Personalizing therapy for older adults with acute myeloid leukemia: Role of geriatric assessment and genetic profiling

Research output: Contribution to journalReview article

9 Scopus citations

Abstract

Acute myeloid leukemia (AML) presents therapeutic challenges in older adults because of high-risk leukemia biology conferring chemoresistance, and poor functional status resulting in increased therapy-related toxicities. Recent FDA approval of 8 new drugs for AML has increased therapeutic armamentarium and also provides effective low-intensity treatment options. Rational therapy selection strategies that consider individual's risk of therapy-related toxicities and probability of disease control can maximize benefits of available treatments. Studies have demonstrated that fitness level, measured by geriatric assessment can predict therapy-related toxicities, whereas cytogenetic and mutation results correlate with the probability of responses to standard chemotherapy. We are approaching an era when we move from “one size fits all” approach to personalized therapy selection based on geriatric assessment, genetic and molecular profiling.

Original languageEnglish (US)
Pages (from-to)52-61
Number of pages10
JournalCancer Treatment Reviews
Volume75
DOIs
StatePublished - May 2019

Keywords

  • Acute myeloid leukemia
  • Genetic profiling
  • Geriatric assessment
  • Molecular mutation
  • Older adults
  • Therapy selection

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Personalizing therapy for older adults with acute myeloid leukemia: Role of geriatric assessment and genetic profiling'. Together they form a unique fingerprint.

  • Cite this